Research ArticleArticle
Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT3A Receptor
Lucy Kate Ladefoged, Lachlan Munro, Anders J. Pedersen, Sarah C. R. Lummis, Benny Bang-Andersen, Thomas Balle, Birgit Schiøtt and Anders S. Kristensen
Molecular Pharmacology December 2018, 94 (6) 1421-1434; DOI: https://doi.org/10.1124/mol.118.113530
Lucy Kate Ladefoged
Interdisciplinary Nanoscience Center, Department of Chemistry, Aarhus University, Aarhus, Denmark (L.K.L., B.S.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (L.M., A.J.P., A.S.K.); Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (S.C.R.L.); Lundbeck Research, H. Lundbeck A/S, Valby, Denmark (B.B.-A.); and Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (T.B.)
Lachlan Munro
Interdisciplinary Nanoscience Center, Department of Chemistry, Aarhus University, Aarhus, Denmark (L.K.L., B.S.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (L.M., A.J.P., A.S.K.); Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (S.C.R.L.); Lundbeck Research, H. Lundbeck A/S, Valby, Denmark (B.B.-A.); and Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (T.B.)
Anders J. Pedersen
Interdisciplinary Nanoscience Center, Department of Chemistry, Aarhus University, Aarhus, Denmark (L.K.L., B.S.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (L.M., A.J.P., A.S.K.); Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (S.C.R.L.); Lundbeck Research, H. Lundbeck A/S, Valby, Denmark (B.B.-A.); and Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (T.B.)
Sarah C. R. Lummis
Interdisciplinary Nanoscience Center, Department of Chemistry, Aarhus University, Aarhus, Denmark (L.K.L., B.S.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (L.M., A.J.P., A.S.K.); Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (S.C.R.L.); Lundbeck Research, H. Lundbeck A/S, Valby, Denmark (B.B.-A.); and Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (T.B.)
Benny Bang-Andersen
Interdisciplinary Nanoscience Center, Department of Chemistry, Aarhus University, Aarhus, Denmark (L.K.L., B.S.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (L.M., A.J.P., A.S.K.); Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (S.C.R.L.); Lundbeck Research, H. Lundbeck A/S, Valby, Denmark (B.B.-A.); and Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (T.B.)
Thomas Balle
Interdisciplinary Nanoscience Center, Department of Chemistry, Aarhus University, Aarhus, Denmark (L.K.L., B.S.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (L.M., A.J.P., A.S.K.); Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (S.C.R.L.); Lundbeck Research, H. Lundbeck A/S, Valby, Denmark (B.B.-A.); and Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (T.B.)
Birgit Schiøtt
Interdisciplinary Nanoscience Center, Department of Chemistry, Aarhus University, Aarhus, Denmark (L.K.L., B.S.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (L.M., A.J.P., A.S.K.); Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (S.C.R.L.); Lundbeck Research, H. Lundbeck A/S, Valby, Denmark (B.B.-A.); and Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (T.B.)
Anders S. Kristensen
Interdisciplinary Nanoscience Center, Department of Chemistry, Aarhus University, Aarhus, Denmark (L.K.L., B.S.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (L.M., A.J.P., A.S.K.); Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (S.C.R.L.); Lundbeck Research, H. Lundbeck A/S, Valby, Denmark (B.B.-A.); and Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia (T.B.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Binding of Vortioxetine at the Human 5-HT3A Receptor
Lucy Kate Ladefoged, Lachlan Munro, Anders J. Pedersen, Sarah C. R. Lummis, Benny Bang-Andersen, Thomas Balle, Birgit Schiøtt and Anders S. Kristensen
Molecular Pharmacology December 1, 2018, 94 (6) 1421-1434; DOI: https://doi.org/10.1124/mol.118.113530
Research ArticleArticle
Binding of Vortioxetine at the Human 5-HT3A Receptor
Lucy Kate Ladefoged, Lachlan Munro, Anders J. Pedersen, Sarah C. R. Lummis, Benny Bang-Andersen, Thomas Balle, Birgit Schiøtt and Anders S. Kristensen
Molecular Pharmacology December 1, 2018, 94 (6) 1421-1434; DOI: https://doi.org/10.1124/mol.118.113530
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement